PURPOSE: The aim of this study was to validate quantitative metabolic response of tumors to a treatment measured by longitudinal 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) micro positron emission tomography (microPET) as a robust tool for preclinical evaluation of new anticancer agents. PROCEDURES: Severe combined immunodeficiency mice with CWR22 xenografts were intravenously treated with bortezomib (Velcade) at 0.8 mg/kg on days 0, 3, 7, 10, and 14 and imaged with FDG microPET before, during and after treatment. Quantitative indices of tumor FDG uptake were developed. RESULTS: FDG microPET images successfully revealed the gradual reduction of tumor FDG uptake on day 4 onward despite no absolute tumor shrinkage. The standardized uptake values of FDG in tumors was reduced to 43% of the baseline values. Using the total tumor FDG uptake as the viable tumor burden, we found 86% tumor inhibition, compared to a 55% tumor growth inhibition in tumor volume measurement. CONCLUSION: FDG microPET imaging can provide an additional dimension of the efficacy of anticancer therapies that may otherwise be underestimated by tumor volume measurement.
PURPOSE: The aim of this study was to validate quantitative metabolic response of tumors to a treatment measured by longitudinal 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) micro positron emission tomography (microPET) as a robust tool for preclinical evaluation of new anticancer agents. PROCEDURES: Severe combined immunodeficiencymice with CWR22 xenografts were intravenously treated with bortezomib (Velcade) at 0.8 mg/kg on days 0, 3, 7, 10, and 14 and imaged with FDG microPET before, during and after treatment. Quantitative indices of tumorFDG uptake were developed. RESULTS:FDG microPET images successfully revealed the gradual reduction of tumorFDG uptake on day 4 onward despite no absolute tumor shrinkage. The standardized uptake values of FDG in tumors was reduced to 43% of the baseline values. Using the total tumorFDG uptake as the viable tumor burden, we found 86% tumor inhibition, compared to a 55% tumor growth inhibition in tumor volume measurement. CONCLUSION:FDG microPET imaging can provide an additional dimension of the efficacy of anticancer therapies that may otherwise be underestimated by tumor volume measurement.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Nobuyuki Oyama; Joonyoung Kim; Lynne A Jones; Nicole M Mercer; John A Engelbach; Terry L Sharp; Michael J Welch Journal: Nucl Med Biol Date: 2002-11 Impact factor: 2.408
Authors: Michael D Henry; Shenghua Wen; Matthew D Silva; Sudeep Chandra; Mark Milton; Peter J Worland Journal: Cancer Res Date: 2004-11-01 Impact factor: 12.701
Authors: Jeffrey S Ross; David P Schenkein; Robert Pietrusko; Mark Rolfe; Gerald P Linette; James Stec; Nancy E Stagliano; Geoffrey S Ginsburg; W Fraser Symmans; Lajos Pusztai; Gabriel N Hortobagyi Journal: Am J Clin Pathol Date: 2004-10 Impact factor: 2.493
Authors: Aniket S Wadajkar; Tejaswi Kadapure; Yi Zhang; Weina Cui; Kytai T Nguyen; Jian Yang Journal: Adv Healthc Mater Date: 2012-07 Impact factor: 9.933
Authors: Neale S Mason; Brian J Lopresti; James Ruszkiewicz; Xinxin Dong; Sonali Joyce; George Leef; Malabika Sen; Abdus S Wahed; Chester A Mathis; Jennifer R Grandis; Sufi M Thomas Journal: Am J Nucl Med Mol Imaging Date: 2013-01-05